00000nam a22000004a 4500 UP-8027258850631488548 Buklod 20240812150654.0 m |o d | ta 240812s2024 xxu r |||| u|eng d PHARM rda eng UPM eThesis LG 993.5 2024 P5 G89 Guzman, Aevelle Krista G. author A retrospective drug utilization review on the use of azithromycin for COVID -19 in a tertiary care public hospital in the Philippines Aevelle Krista G. Guzman, Rachelle Diño ; Mac Ardy J. Gloria, adviser. Manila: Department of Pharmacy, College of Pharmacy, University of the Philippines Manila 2024 xi, 118 leaves ; 28 cm. text rdacontent unmediated rdamedia volume rdacarrier Thesis (Bachelor of Science in Pharmacy)--University of the Philippines Manila, June 2024 available to general public Introduction: Azithromycin (AZM) was investigated as a repurposed drug against COVID-19 infection, yet findings from multiple randomized clinical trials indicated it does not offer significant advantages over standard care alone. Consequently, various clinical practice guidelines (CPGs), including the Philippine COVID-19 Living CPG, recommended against its use for COVID-19. Nonetheless, its continued use was observed in two tertiary public hospitals in 2021, particularly in critical cases. Objectives: This study aimed to determine the prevalence of AZM prescribing for COVID-19, describe its associated drug therapy problems (DTPs), and estimate the direct drug costs. Methods: Data were collected from randomly selected medical records of 18 to 59 year old COVID-19 inpatients admitted on or between April 27, 2021 to May 5, 2023. Patients who were re-infected, had co-infection warranting AZM use during admission, pregnant, lactating, transferred to another hospital, or had incomplete information were excluded. Pertinent data were analyzed using descriptive statistics. Results: Among the 191 medical records reviewed, 82 cases of AZM prescription for the past three years were identified with critical severity (37.50%) having the most cases in 2021, severe (43.75%) in 2022, and severe (50.00%) and critical cases (50.00%) in 2023. For DTPs, there were 82 cases of unnecessary drug therapy (42.93%), 16 cases of adverse drug reactions (19.51%), and 5 cases of contraindicated use (2.62%). An average cost of PhP 254.90 associated with AZM use and PhP 408.00 associated with AZM use plus DTP management were estimated for direct drug costs. xii Conclusion: Over the past three years, AZM prescription and use have been observed, especially in severe to critical COVID-19 cases where poor adherence to CPG has previously been reported. This highlights the need to develop more stringent guidelines promoting antimicrobial stewardship and policy recommendations regarding mandatory adherence to CPGs. Drug utilization Reviews Philippines. Azithromycin Therapeutic uses Philippines. COVID-19 (Disease) Retrospective studies. Philippines . Tertiary care hospitals. Diño, Rachelle author . Gloria, Mac Ardy J. adviser . FI UP UPMNL PHARM LG 993.5 2024 P5 G89 Thesis